[Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?] / Zielgerichtete Therapie beim metastasierten Mammakarzinom welche molekularen Tests sind notwendig?
J Gynakol Endokrinol
; 30(2): 64-66, 2020.
Article
in German
| MEDLINE | ID: covidwho-458960
ABSTRACT
In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the detection of mutations in the breast cancer 1 (BRCA1) or BRCA2 gene in the patient's germline and mutations in the phosphatidylinositol 3 kinase (PI3K) pathway are currently relevant when making decisions regarding targeted therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
German
Journal:
J Gynakol Endokrinol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS